Pfizer, Moderna shares plummet after Biden administration backs a COVID-19 vaccine patent waiver
The United States will advocate for waiving COVID-19 vaccine patent protections in discussions with the World Trade Organization, U.S. Trade Representative Katherine Tai announced Wednesday.
The Biden administration "believes strongly in intellectual property protections," Tai said in a statement, but the White House will back the waiver given the "extraordinary circumstances of the COVID-19 pandemic." The administration has faced pressure to support the measure, which is aimed at increasing vaccinations around the world — especially in countries experiencing a surge in infections, like India — without having to rely solely on exports.
These extraordinary times and circumstances of call for extraordinary measures.
The US supports the waiver of IP protections on COVID-19 vaccines to help end the pandemic and we’ll actively participate in @WTO negotiations to make that happen. pic.twitter.com/96ERlboZS8
— Ambassador Katherine Tai (@AmbassadorTai) May 5, 2021
Proponents were pleased with the news, but shortly after Tai's announcement, stocks of pharmaceutical companies that have produced vaccines, including Moderna and Pfizer, plummeted.
I seems the Biden administration has decided to throw its weight behind a patent waiver on Covid vaccines. This is what it's doing to the vaccine makers' share prices. pic.twitter.com/zwh4Aekmvj
— Kiran Stacey (@kiranstacey) May 5, 2021
It remains unclear if the protections will actually be waived since all 164 members of the WTO will need to agree on the matter, but backing from the U.S. should certainly move the needle.
More stories from theweek.com
5 brutally funny cartoons about the GOP's shunning of Liz Cheney
Conservatives say McConnell is battling the Democrats' voting rights bill with 'Supreme Court fight' fervor
Liz Cheney's heresy
